Alumis Inc.
NASDAQ · ALMS·South San Francisco, CA·Mid-cap·Phase 3
Late-stage clinical biopharma developing next-generation targeted therapies for immune-mediated diseases, anchored by oral allosteric TYK2 inhibitor envudeucitinib (ESK-001), which hit primary and secondary endpoints in the Phase 3 ONWARD plaque psoriasis program with an NDA planned for 2H 2026. Pipeline expanded via the May 2025 ACELYRIN merger to include subcutaneous anti-IGF-1R antibody lonigutamab for thyroid eye disease and CNS-penetrant TYK2 inhibitor A-005 for neuroinflammatory disease.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Alumis Corporate Presentation | Corporate overview | March 1, 2026 | 34 |